导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.11% | 2847/4773 |
| 近一周 | -2.29% | 1692/5462 |
| 近一月 | -4.42% | 2458/5421 |
| 近一季 | -7.89% | 2570/5209 |
| 近半年 | -2.97% | 2082/4920 |
| 近一年 | 0.40% | 2577/4366 |
| 近两年 | 47.54% | 1557/2954 |
| 近三年 | 29.44% | 1077/2253 |
| 成立以来 | 55.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.66% 3340/4961 |
12.51% 2166/5312 |
- - |
- - |
| 2025 | 20.90% 2071/4813 |
-0.93% 2476/3635 |
2.36% 1617/4076 |
19.03% 2201/4524 |
0.16% 2173/4813 |
| 2024 | 17.84% 648/3463 |
3.11% 622/2808 |
-1.11% 937/3014 |
17.74% 1129/3129 |
-1.84% 1856/3463 |
| 2023 | -8.99% 1083/2656 |
4.60% 912/2280 |
-3.96% 984/2385 |
-2.88% 779/2515 |
-6.72% 1888/2655 |
| 2022 | -19.51% 857/2207 |
-14.24% 922/1919 |
7.06% 538/2016 |
-13.91% 991/2113 |
1.84% 1122/2208 |
| 2021 | 4.05% 592/1822 |
-1.52% 507/1255 |
7.00% 709/1330 |
-3.65% 650/1466 |
2.48% 581/1822 |
| 2020 | 39.02% 342/1250 |
-9.92% 731/1028 |
14.05% 574/1067 |
16.51% 149/1164 |
16.14% 182/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 民生加银沪深300ETF VS. 长安沪深300非周期A(740101) |